A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia.
AUTHORS
Donnellan
W ,
Berdeja
JG ,
Shipley
D ,
Arrowsmith
ER ,
Wright
D ,
Lunin
S ,
Brown
R ,
Essell
JH ,
Flinn
IW ,
. The oncologist. 2017 7 7; ().
- PMID: 28687625 [PubMed].
ABSTRACT
Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions.
Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions.
Tags: Alumni Publications 2017